Expression and clinical significance of B-cell lymphoma 2 (BCL-2) in hyperleukocytic acute myeloid leukemia / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 851-856, 2013.
Artículo
en Chino
| WPRIM
| ID: wpr-284021
ABSTRACT
This study was aimed to investigate the role of B-cell lymphoma 2 (BCL-2) in pathogenesis of hyperleukocytic acute myeloid leukemia (AML). The levels of intracellular BCL-2 in 48 AML patients were detected by flow cytometry (FCM). Serum levels of BCL-2 in 40 AML patients were measured by enzyme-linked immunosorbent assay (ELISA). The results showed that the serum levels of BCL-2 in hyperleukocytic AML and non-hyperleukocytic AML patients were significantly higher than that in normal controls (P < 0.05), but intracellular BCL-2 levels were not significantly different, as compared with normal controls (P > 0.05). There were no difference of intracellular and serum BCL-2 levels between hyperleukocytic and non-hyperleukocytic AML patients (P > 0.05). The serum and intracellular levels of BCL-2 between hyperleukocytic AML, non-hyperleukocytic AML patients and normal controls were not statistically correlated. It is concluded that leukemic cells in AML patients produce and secrete too much BCL-2, which may be involved in the pathogenesis of leukemia disease. However, the anti-apoptosis effect of BCL-2 has no significant impact on the pathogenesis of hyperleukocytic AML.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Patología
/
Sangre
/
Leucemia Mieloide Aguda
/
Estudios de Casos y Controles
/
Proteínas Proto-Oncogénicas c-bcl-2
/
Citometría de Flujo
Tipo de estudio:
Estudio observacional
Límite:
Femenino
/
Humanos
/
Masculino
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2013
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS